Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety

被引：0

作者：

Fabien Huet

Mariama Akodad

Eran Kalmanovitch

Jerome Adda

Audrey Agullo

Pascal Batistella

Camille Roubille

François Roubille

机构：

[1] Hôpital Arnaud de Villeneuve,Département de Cardiologie

[2] CHU de Montpellier,Department of Internal Medicine and Hypertension

[3] UFR de Médecine,undefined

[4] Université Montpellier 1,undefined

[5] PhyMedExp,undefined

[6] University of Montpellier,undefined

[7] INSERM U1046,undefined

[8] CNRS,undefined

[9] UMR 9214,undefined

[10] Montpellier University Hospital,undefined

来源：

American Journal of Cardiovascular Drugs | 2019年 / 19卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties).

引用

页码：1 / 10

页数：9

共 50 条

[41] Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center
Yao, Zhuan'e
Wang, Pengbo
Fu, Qinjuan
Song, Qiong
Liu, Ai
Li, Huan
Wang, Wei
Zhang, Peng
MEDICAL SCIENCE MONITOR, 2024, 30
[42] Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials
Zhang, Hongzhou
Huang, Tieqiu
Shen, Wen
Xu, Xiuxiu
Yang, Pingping
Zhu, Dan
Fang, Haiyang
Wan, Hongbing
Wu, Tao
Wu, Yanqing
Wu, Qinghua
ESC HEART FAILURE, 2020, 7 (06): : 3841 - 3850
[43] Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension
Supasyndh, Ouppatham
Sun, Ningling
Kario, Kazuomi
Hafeez, Kudsia
Zhang, Jack
HYPERTENSION RESEARCH, 2017, 40 (05) : 472 - 476
[44] Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry)
Jimenez-Blanco Bravo, Marta
Valle, Alfonso
Gayan Ordas, Jara
del Prado Diaz, Susana
Cordero Pereda, David
Morillas Climent, Herminio
Bascompte Claret, Ramon
Seller Moya, Julia
Zamorano Gomez, Jose Luis
Alonso Salinas, Gonzalo Luis
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 78 (05) : e662 - e668
[45] Safety and efficacy of the combination of sacubitril/valsartan and SGLT2i in HFrEF patients (SECSI Registry)
Marta Jimenez-Blanco Bravo, M.
Del Prado Diaz, S.
Cordero Pereda, D.
Zamorano, J. L.
Alonso Salinas, G.
EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 368 - 369
[46] Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension
Ouppatham Supasyndh
Ningling Sun
Kazuomi Kario
Kudsia Hafeez
Jack Zhang
Hypertension Research, 2017, 40 : 472 - 476
[47] Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results
Owens, Ryan E.
Oliphant, Carrie S.
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2017, 30 (04) : 556 - 557
[48] Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension
Tocci, Giuliano
CARDIOLOGY, 2020, 145 (09) : 599 - 600
[49] Tolerability and safety of Sacubitril/Valsartan in real-life practice
Joana Neiva, J. N.
Gomez-Otero, I. G. O.
Varela-Roman, A. V. R.
Moure Gonzalez, M. M. G.
Seoane Blanco, A. S. B.
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 73 - 73
[50] Tolerability and safety of sacubitril/valsartan in high-risk subgroups
Neiva, J. N.
Gomez-Otero, I. G. O.
Varela-Roman, A. V. R.
Moure Gonzalez, M. M. G.
Seoane Blanco, A. S. B.
Gonzalez-Juanatey, J. R. G. J.
EUROPEAN HEART JOURNAL, 2018, 39 : 174 - 175

← 1 2 3 4 5 →